Thrombolytic therapy with recombinant tissue plasminogen activator was uncommonly used in Kazakhstan during the patient enrollment period (2009–2013) because of access and the likelihood of presentation to hospital more than 4.5 h after stroke onset, therefore, none of the patients in our study received this intervention. The gene discussed is PLAT; the disease is Stroke.